^
    Back
    Association details:
    Biomarker:CDKN2A mutation
    Cancer:Urothelial Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    CDKN2A Alterations and Response to Immunotherapy in Solid Tumors

    Published date:
    06/01/2021
    Excerpt:
    In the DFCI cohort, CDKN2A GAs were associated with poor response and survival in patients with urothelial carcinoma treated with ICIs...CDKN2A GAs were associated with worse outcomes in the MSKCC urothelial carcinoma cohort treated with ICIs.
    DOI:
    10.1158/1078-0432.CCR-21-0575
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO-GU 2021
    Title:

    CDKN2A alterations as markers of immune checkpoint blockade (ICB) resistance in urothelial carcinoma (UC).

    Published date:
    02/08/2021
    Excerpt:
    CDKN2A alterations were significantly associated with shorter OS and TTF in the DFCI UC and melanoma cohorts by MVA, and showed a trend towards significance in the MSKCC UC cohort (Table).
    DOI:
    10.1200/JCO.2021.39.6_suppl.475